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Abstract
Mitochondrial dysfunction and elevated reactive oxygen species (ROS) levels are strongly
implicated in various neurodegenerative disorders, including Huntington’s disease (HD).
Expression of the mutant Huntingtin protein (mHTT) containing an expanded polyglutamine
repeat is associated with oxidative stress and toxicity in striatal neurons. Nuclear factor
erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor responsible for
regulating expression of a diverse array of antioxidant and cytoprotective genes. Most known
Nrf2-activating compounds act through the canonical pathway by mimicking a transient
oxidative insult, and treatment effects are short-lived. This study reveals an increase in
striatal cell viability, and a reduction in mitochondrial reactive oxygen species (ROS) levels,
following treatment with the non-canonical Nrf2-activator 2,3-dimercaptopropanol (DMP).
DMP was also found to prevent the formation of Keap1- and Nrf2-positive inclusion bodies.
The current study highlights previously unknown intracellular targets of DMP and indicates
that this FDA approved compound may have relevance for the treatment of HD and other
neurodegenerative disorders.
Keywords: Huntington’s disease, HD, antioxidant, ROS, DMP, BAL
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Chapter 1 : Introduction
1.1

Huntington’s Disease Overview

Huntington’s disease (HD) is a fatal, progressive neurological disorder characterized by
mid-life onset and gradual worsening of motor dysfunction, emotional disturbances, and
cognitive decline, with death occurring 15-20 years from onset. The disease was named
after George Huntington, the American doctor who described a patient with classical
symptoms of the condition in 1872 (Huntington, 1872). HD affects roughly 1 in every
7,000 Canadians (Huntington Society of Canada, 2014), and 5-10 individuals per 100,000
worldwide, making it the most common inherited neurodegenerative disorder (Landles
and Bates, 2004). The disease is caused by a dominantly inherited CAG trinucleotide
repeat expansion in the HD gene (HTT) encoding the multi-functional huntingtin protein
(HTT). The expansion results in an extended polyglutamine domain that promotes protein
misfolding and causes neuronal cell death in a number of brain regions. Although HD is a
monogenic disease, symptom onset and progression appears to be relatively variable
among affected individuals (Kirkwood et al., 2001). A number of studies have reported
that age at onset decreases and disease severity increases with increasing lengths of the
CAG repeat (Andrew et al., 1993; Claes et al., 1995; Ruocco et al., 2006). Although HD
most commonly manifests during the third to fifth decades of life, studies have revealed
that the age of onset follows an essentially normal distribution. Surveys have shown that
approximately 5-10% of cases are juvenile-onset and present in persons less than 20
years of age, and even fewer cases present after the age of 60 (Ribaï et al. 2007; Lipe &
Bird, 2009; Nance & Myers, 2001). Patients with adult-onset HD, which represents the
majority of cases, typically develop mood imbalances, such as depression and irritability,
prior to the onset of movement disorders (Duff et al., 2007). Nevertheless, the definitive
clinical feature of HD is chorea: a hyperkinesia characterized by abrupt, unpredictable,
involuntary movements that, in early HD, makes the patient appear clumsy or fidgety.
However, as the involuntary movements increase in frequency and amplitude they begin
to interfere with normal speech, swallowing, posture, and gait. Moreover, HD patients
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have an increased risk of skin injuries, infections, bone fractures and even head trauma in
the mid to late stages of the disease. In the end stages of the disease, patients develop
dystonic postures, rigidity, and full dementia (Di Maio et al., 1993). Due to the
widespread expression of the affected protein, HD patients also exhibit abnormalities in
peripheral tissues, such as muscle atrophy and dramatic weight loss (Sanberg et al., 1981;
Trejo et al., 2004). The leading causes of death arise from complications associated with
immobility, such as pneumonia, cardiac disease, and infection. However, due to the
progressive loss of behavioural control and cognitive ability, suicide risk is much higher
in HD patients, and accounts for almost 10% of patient deaths (Baliko et al., 2004; Di
Maio et al., 1993 Heemskerk & Roos, 2010).
The pathological hallmark of HD is the striking degeneration of the caudate nucleus and
the putamen, together known as the striatum (Ruocco et al., 2006). The GABAergic
medium spiny projection neurons (MSNs) constitute the majority of neurons in the
striatum and appear to be particularly susceptible to the toxicity associated with mutant
huntingtin protein (mHTT) expression. MSNs receive excitatory input from the entire
cerebral cortex and thalamus, and provide an inhibitory output to areas of the brain that
are involved in the regulation of voluntary movement, such as the globus pallidus and the
substantia nigra pars reticulata. This loss of inhibitory innervation is thought to be the
cause of chorea in early to mid-stage HD. Additionally, there is substantial cortical
neuron cell death, severe loss of subcortical white matter, and enlargement of the
ventricles (Suzanne, Vonsattel & Richardson, 1988). The collective neuropathologies
associated with HD give the appearance of a shrinking brain; by the late stages of HD an
afflicted brain can weigh 20-30% less than a healthy brain, depending on the severity of
the disease (Vonsattel & DiFiglia, 1998).
There is currently no cure for HD, and the current drug therapies possess no ability to
delay the onset or slow the progression of the disease. Pharmacotherapies typically used
to manage the movement disorders of HD act by rebalancing the neurotransmitters in the
basal ganglia (Erdemoglu and Boratav, 2002). However, these medications have limited
utility due to a number of worrisome side effects, such as Parkinsonism, loss of balance,
and dysphagia, as well as an exacerbation of a number of psychiatric symptoms, such as
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depression. Several psychiatric disturbances also respond well to pharmacological
intervention; most commonly patients are prescribed antidepressants and anti-psychotics
with a variety of mechanisms of action (Erdemoglu and Boratav, 2002; Ford, 1986).
Patients receive a drug regimen tailored to their particular constellation of movement and
psychiatric symptoms; however, in many cases, the efficacies of pharmacological
intervention are modest, and the behavioural symptoms associated with the disease make
noncompliance a prevalent issue in symptomatically treating HD patients (Armstrong et
al., 2012; Bonelli and Hofmann, 2007). In light of this, there has been a shift in research
focus toward the development of neuroprotective treatment strategies. This approach is
beneficial in that it has the potential to slow or halt disease progression. Several studies
have looked at agents that confer neuroprotection by disrupting the transcription of
mHTT (Ryu et al., 2005), or interfering with harmful mHTT-protein interactions (Bauer
et al., 2010; Li and Li, 2004; Slow et al., 2006). More general neuroprotective agents,
such as apoptosis inhibitors (Chen et al., 2000) and drugs that upregulate transcription of
cytoprotective or antioxidant genes (Huntington Study Group, 2001; Ranen et al., 1996),
have shown promise; however, much more research needs to be done.

1.2

Molecular Basis for HD

The gene responsible for HD (HTT) was molecularly mapped to the short arm of human
chromosome four in 1983 (Gusella et al., 1983), and the nature of the causative mutation
was teased out nearly a decade later (MacDonald et al., 1993). The HD gene encodes a
multi-functional, 350kDa protein called huntingtin (HTT), which is ubiquitously
expressed throughout the central nervous system, in peripheral tissues, and during
embryonic development (Bhide et al., 1996; Strong et al., 1993). The HD mutation
comprises an unstable DNA segment caused by a polymorphic expansion of the (CAG)n
repeat within exon 1 of the HD gene. The resultant expansion in the number of glutamine
residues in the polyglutamine (polyQ) repeat region of the huntingtin protein is predictive
of both the age of onset and the severity of the disease (MacDonald et al., 1993). The
expanded polyglutamine region makes the mutant huntingtin protein (mHTT) highly
susceptible to misfolding and aggregation, which is thought to lead to the formation of
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toxic intracellular inclusion bodies (Landles and Bates, 2004). This susceptibility rises
with increasing CAG repeat lengths: HTT alleles within the range (CAG)6-35 are nonpathogenic and result in a normal phenotype, whereas individuals possessing alleles
within the range (CAG)36-39 are only at an increasing risk of developing the disease, and
alleles with (CAG)40 or higher are associated with fully penetrant HD. Approximately 57% of afflicted individuals possess alleles of (CAG)70 or higher and present with
juvenile-onset HD (Nance and Myers, 2001).
Wildtype huntingtin (wt HTT) is mostly cytoplasmic, with a small intranuclear portion.
The complete repertoire of HTT cellular functions is still not clearly defined because it
contains little sequence homology to other known proteins (MacDonald et al., 1993). One
important region in the protein is the polyQ region; it begins at the eighteenth amino acid
from the NH2-terminus and forms a polar zipper structure, which functions to bind
transcription factors that also contain a polyQ stretch (Li and Li, 2004; Perutz et al.,
1994). Downstream from this, HTT contains multiple HEAT (Huntingtin, Elongation
factor 3, protein phosphatase 2A, and the lipid kinase TOR) repeat sequences. HEAT
repeats are 30-40 amino acid motifs comprised of two anti-parallel α-helices. These
motifs often assemble into superhelical structures with continuous hydrophobic cores
(Andrade and Bork, 1995), which indicates that HTT may play a scaffolding role in
facilitating protein-protein interactions. Huntingtin also contains functionally active
nuclear export/localization signals at the carboxy terminus, implicating the protein in
nuclear-cytoplasmic transportation (Xia et al., 2003). Some of these roles include
clathrin-mediated transport of endocytic and secretory vesicles (Velier et al., 1998), and
interacting with huntingtin-interacting proteins (HIPs) and huntingtin-associated proteins
(HAPs; Neuwald & Hirano, 2000; Takano and Gusella, 2002).
The necessity of HTT during different stages of development is demonstrated by a
number of studies that experimentally reduced the wildtype protein levels. Embryonic
lethality occurs prior to gastrulation and formation of the nervous system in huntingtinknockout mice (Hdh-/- ; Zeitlin, et al., 1995). Additionally, heterozygote (Hdh+/-) and
Hdh-knockdown (<50%) studies suggest that, following gastrulation, normal levels of
wildtype HTT become essential for proper neurogenesis and formation of the cortex and
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striatum (Nasir et al., 1995; White et al., 1997). Interestingly, during development the
expression of mHTT can compensate for the absence of wildtype huntingtin (Leavitt et
al., 2001), and individuals that are homozygous for mHTT are born without neurological
defects (Wexler et al., 1987). This indicates that, during development, the HD mutation
does not interfere with the function of normal huntingtin, and does not confer a toxic
gain-of-function. Furthermore, patients possessing just a single fully functional
huntingtin allele do not develop HD, which provides evidence that the disease is not
exclusively caused by the loss of huntingtin function (Ambrose et al., 1994).
In post-mitotic brain cells and adulthood, the altered protein structure that results from
the polyQ expansion gives rise to aberrant protein interactions that cause cytotoxicity and
simultaneously interfere with normal huntingtin function. Wildtype (wt) HTT, but not
mHTT, also plays a critical role in the transcriptional regulation (Zuccato et al., 2001)
and anterograde transportation of brain-derived neurotrophic factor (BDNF) from cortical
cells to the striatum, where it provides neurotrophic support for striatal cell survival and
maintains the integrity of the cortico-striatal synapses (Gauthier et al., 2004). The
presence of mHTT or a decrease in the levels of wt HTT both drastically reduce the
striatal levels of BDNF and may partially account for the increased susceptibility of
medium spiny neurons in HD (Zuccato et al., 2001; del Toro et al., 2006). Interestingly,
the function of huntingtin as an effective transport molecule seems to hinge upon posttranslational modifications, which are disturbed in mHTT (Zala et al., 2008). The polyQ
expansion in mHTT impairs its nuclear export capabilities (Cornett et al., 2005). A
number of studies have shown that HTT has anti-apoptotic properties: in vitro studies of
conditionally-immortalized striatal cells over-expressing the human wildtype protein
have shown that wt HTT exerts its protective effects by preventing the activation of
caspase-3, possibly at the level of caspase-9 (Rigamonti et al., 2000). Moreover,
overexpression of wt HTT confers gene dose-dependent neuroprotection against
ischaemic injury in vivo (Zhang et al., 2003), excitotoxicity (Leavitt et al., 2006), and is
also able to alleviate the harmful effects of the mutant protein (Rigamonti et al., 2001),
which suggests that the HD neuropathology can likely be partially attributed to a loss of
the wildtype huntingtin function.
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The mutant huntingtin protein also bears a toxic gain-of-function, which is commonly
attributed to its propensity for novel protein-protein interactions and aggregation into
fibrillar strands, which ultimately form large intracellular inclusion bodies (Butterfield &
Kanksi, 2001). The production of cytotoxic HTT fragments is a central component of HD
pathogenesis. The N-terminal region of HTT is a common cleavage site for a number of
proteases, and in vitro studies have revealed that the polyQ expansion observed in HD
enhances the cytotoxicity of proteolytically cleaved HTT (Hackam et al., 1998). Indeed,
the intracellular, and often nuclear, accumulation of N-terminal mHTT fragments is a
neuropathological hallmark of HD (Hackam et al., 1998). In a mouse model of HD that
expresses the full-length mutant huntingtin protein, researchers found that the nuclear
localization of huntingtin fragments occurred first and most drastically in the striatum,
which could account for the regional sensitivity in the disease (Van Raamsdonk et al.,
2005). Further studies revealed that the same mice now expressing a caspase-6-resistant
version of mHTT do not develop striatal neurodegeneration, and are actually protected
against stressor-induced neurotoxicity (Graham et al., 2006). Following cleavage by
caspase-6, transglutaminases catalyze the covalent cross-linking of mHTT N-terminal
fragments to form cytotoxic oligomers. These oligomers increase in number within the
cytoplasm until they reach a threshold concentration, at which point a nucleation event
occurs, triggering the formation of inclusion bodies (Ossato et al., 2010; Zainelli et al.,
2005). Aggregates of mHTT have been reported to act as physical roadblocks impairing
mitochondrial movement (Chang et al., 2006), and mHTT oligomers directly interfere
with microtubule-associated axonal transport by binding key motor proteins. This may
contribute to the enhanced susceptibility of the MSNs in the striatum due to their
extensive dendritic branching (Trushina et al., 2004).

1.3

Oxidative Stress in HD Neurodegeneration

Redox homeostasis is essential for proper neuronal function and its perturbation, resulting
in oxidative stress, is often implicated in triggering cell death pathways in
neurodegenerative diseases associated with protein aggregates, including HD (Martínez
et al., 2010). The redox state of a cell is defined by its ability to balance the production of
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reactive oxygen species (ROS) with its antioxidant defense capacity. ROS are unstable,
oxygen-containing molecules that are generated by the sequential reduction of oxygen
during a number of normal cell processes. They exhibit profound reactivity due to the
unpaired electron in the valence shell of oxygen (Dasuri et al., 2013). Although there are
numerous intracellular sources of ROS, oxidative phosphorylation associated with
mitochondrial electron transport chain (ETC) activity is a major source of the superoxide
radical (O2), which is a precursor for many other reactive species, including hydrogen
peroxide (H2O2), and the more reactive hydroxyl radical (OH; Guidot et al., 1993). The
function of the ETC is to produce useful chemical energy by passing electrons along a
chain of molecules, in which oxygen is the terminal acceptor. Under basal conditions, a
small percentage of the electrons leak out of the ETC and interact with oxygen to form
ROS, which, at normal physiological levels, maintain cell homeostasis and function as
important second messengers in cell signaling by extracting electrons from neighbouring
macromolecules, thereby modifying their biological functions (Sena & Chandel, 2012;
Valko et al., 2004). Proteins containing cysteine residues within their functional domains
are highly sensitive to ROS-mediated modification; oxidation of the sulfhydryl groups
(Cys-SH) can promote the formation of intra-protein disulfide linkages (Cys-S-S-Cys)
thereby altering protein function or interactions with other proteins (Cumming et al.,
2004).
Oxidative stress occurs when there is an excessive production of reactive oxygen species
(ROS), inadequate antioxidant defense capacity, or both, which results in subsequent
cellular damage. When ROS accumulate to high concentrations within the cell, extensive
oxidative damage can impair the normal function of cell components, thereby promoting
disease states. It has been well established that oxidative stress is involved in the
pathogenesis of a number of neurodegenerative diseases, including Alzheimer’s,
Parkinson’s and Huntington’s diseases. Because age is a risk factor in theses diseases,
and we know that ROS increase in the brain with age, we can postulate that ROS plays a
role in pathological neurodegeneration (Mariani et al., 2005). Unwarranted protein
oxidation can result in aberrant protein functions and structure, and can also cause
fragmentation (Berlett & Stadtman, 1997). Oxidation tends to increase the protein’s
hydrophobicity, which may induce protective proteolysis; however, it can also promote
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protein aggregation (Dasuri et al., 2010; Shringarpure et al., 2001).

The brain is

especially susceptible to oxidative stress due to the elevated levels of oxygen
consumption and high polyunsaturated fatty acid content. Peroxidation of phospholipids
compromises the structural integrity of the cell membrane and triggers detrimental free
radical chain reactions, which produce intermediates that form harmful adducts with
DNA (Bartsch, 1997; Porter, 1986). Interestingly, elevated lipid peroxidation products
have been reported in the striatum of huntingtin-overexpressing transgenic mice, as well
as in the cerebrospinal fluid of HD patients (Perez-Severiano et al., 2000; Montine et al.,
1999).

Additionally, direct oxidative damage to nucleic acids in DNA promote

mutagenesis, further implicating oxidative stress in the development of age-dependent
diseases such as cancer and neurodegenerative disorders (Ames et al., 1994; Valko et al.,
2004). Mitochondrial DNA is particularly vulnerable to oxidative damage as a result of
being a major ROS generator coupled with inferior DNA repair mechanisms (Lin & Beal,
2006). A number of studies have provided supporting evidence for a link between
mitochondrial dysfunction and oxidative damage in early and late-stage HD patients, as
well as in animal and cell culture models of HD (Brown & Beal, 2006). Succinate
dehydrogenase (SDH), or respiratory complex II, is a functional member of both the
mitochondrial electron transport chain, and the citric acid cycle. Prolonged systemic
administration of 3-nitropropionic acid (3-NP), an irreversible mitochondrial complex II
inhibitor, to animals induces targeted oxidative stress and neurodegeneration in the
striatum by damaging cell metabolism, which results in a reduction in ATP production.
This causes striatal lesions and gait abnormalities that mimic HD (Beal et al., 1993;
Brouillet et al., 1995). Furthermore, mitochondria isolated from a transgenic mouse
model of HD demonstrate reduced membrane potential and heightened sensitivity to
calcium-induced release of cytochrome c when compared with controls (Panov et al.,
2002). This supports the hypothesis that increased oxidative stress seen in
neurodegenerative diseases confers an increased susceptibility for programmed cell
death.
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1.4

Activation of Nrf2 and the Antioxidant Response

Following the discovery that elevated oxidative stress contributes to these
neurodegenerative diseases, researchers proposed the therapeutic administration of
exogenous antioxidants; however, these treatments did not produce favourable results.
The majority of exogenous antioxidants are hydrophilic and therefore unable to
effectively cross the blood-brain barrier. This, coupled with their toxicity at high doses
makes their therapeutic efficacy quite low (Moosmann & Behl, 2002). In an effort to
more effectively restore redox homeostasis, researchers shifted their target to increasing
expression of endogenous antioxidant enzymes already present in the central nervous
system (Schreibelt et al., 2007). A number of these protective genes conveniently share a
common promotor region, known as the Antioxidant Response Element (ARE), which is
regulated by the transcription factor, Nuclear factor (erythroid-derived 2)-like 2 (Nrf2;
Kensler et al., 2007). ARE target genes include the antioxidant peroxiredoxin-1 (PRX1)
as well as the phase II detoxifying enzymes, such as glutathione-S-transferase (GST) and
heme oxygenase (HO; He & Ma, 2010). Nrf2 is the regulatory transcription factor that
modulates the expression of several antioxidant and cytoprotective genes in order to
maintain and restore redox homeostasis. Under basal conditions (Figure 1, top) Nrf2 is
constitutively expressed but is maintained at very low levels because it is bound in the
cytoplasm by its negative regulator, Kelch like-ECH-associated protein 1 (Keap1). Keap1
binds Nrf2 in the cytoplasm and forms an E3 ubiquitin ligase complex with Cullin-3
(Cul3) in order to poly-ubiquitinate and subsequently degrade Nrf2 via the 26S
proteasome (Villeneuve et al., 2010). The interaction between Nrf2 and Keap1 is thought
to behave like an intracellular sensor of oxidative stress due to its proclivity for
dissociation in the presence of reactive oxygen species and/or electrophiles (Koboyashi et
al., 2004). Following the oxidation of critical cysteine residues, Keap1 undergoes a
conformational change, which causes Nrf2 and Keap1 to detach from the ubiquitin-ligase
complex. This dissociation allows for the stabilization and translocation of Nrf2 into the
nucleus where it dimerizes with small musculoaponeurotic fibrosarcoma oncogene
homolog (Maf) proteins in order to bind to the cis-acting ARE and up-regulate the
transcription of a battery of antioxidant and cytoprotective genes (Itoh et al., 2003).
Additionally, experimental overexpression of Nrf2 was found to be protective against
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oxidative stress induced by the mitochondrial complex II inhibitor 3-NP both in vivo and
in vitro (Calkins et al., 2005). The increased expression of these free radical scavenging
enzymes, which convert toxic ROS to water, comprise a powerful antioxidant defense
against oxidative damage.
A number of known canonical Nrf2-activators act by mimicking a transient oxidative
insult by promoting the dissociation of Nrf2 from the Keap1-Cul3 complex (Figure 1,
left), which causes a subsequent increased expression of key antioxidant proteins
(Nguyen et al., 2004). Indeed there is substantial evidence to support a protective role of
Nrf2-induced antioxidant defense in neurodegeneration. Both tert-butylhydroquinone
(tBHQ) and sulforaphane (SFN), which are canonical Nrf2 activators, were protective
against oxidative stress, neurodegeneration and cerebral ischemia in vivo (Shih et al.,
2005; Zhao et al., 2006). More recently, SFN was found to suppress the formation of a
lesion area, reduce neuronal death, rescue the decrease in succinate dehydrogenase
activity, and reduce the levels of inflammatory mediators in the striatum of a 3-NPinduced mouse model of HD (Jang and Cho, 2015). Given that there exists a wellestablished role of oxidative stress in neurodegenerative diseases such as HD,
therapeutics that aim to increase the endogenous antioxidant defense systems by
enhancing the transcriptional activity of Nrf2 could hypothetically slow disease
progression by increasing the lifespan of affected neurons. Interestingly, an alternative, or
non-canonical, mechanism of Nrf2 activation has been discovered, which involves the
formation of covalent adducts between Keap1 and the electrophile, such as arsenic,
followed by the subsequent autophagosomal degradation of Keap1 (Lau et al., 2010; Lau
et al., 2013). Non-canonical activation of Nrf2 operates through the p62/SQSTM1
(sequestosome 1) protein, which is a selective substrate adapter protein that plays a
critical role in the autophagy process due to its ability to bind both ubiquitinated proteins
as well as the autophagosome-localizing protein, LC3 (Pankiv et al., 2007). Thus p62 can
selectively direct Keap1 towards autophagosomal degradation, thereby allowing the
stabilization and nuclear translocation of Nrf2. To date, the differential protection
conferred by canonical or non-canonical Nrf2 activators for the treatment of HD has not
yet been explored; however, a recent study suggests that non-canonical activators, such as
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2,3-dimercaptopropanol (DMP) may elicit a potent and prolonged activation of Nrf2
(Pitts et al., 2012).

1.5

2,3-Dimercaptopropanol

2,3-Dimercaptopropanol (DMP), also known as British anti-lewisite (BAL), is a heavy
metal-chelating dithiol compound that was developed in 1940 as an antidote to the
arsenic-based chemical warfare agent lewisite (Waters & Stock, 1945). Arsenic and other
heavy metals form complexes with and inactivate sulfhydryl-containing proteins and
enzymes. One such enzyme, pyruvate dehydrogenase, is essential for pyruvate
metabolism, and its inhibition leads to lactic acidosis and cell death (Petrick et al., 2001).
DMP is more stable than naturally occuring dithiols, and because heavy metals prefer to
form complexes with stable thiol complexes, treatment with DMP reverses the inhibition
of these essential enzymes, thereby ameliorating their toxic effects (Vilensky & Redman,
2003). In 1951 DMP was successfully used to treat patients with hepatolenticular
degeneration resulting from copper accumulation in the liver (Denny-Brown & Porter,
1951). At this time, HD was thought to be caused by copper accumulation in the brain
(Vilensky & Redman, 2003) and DMP was administered daily to two HD patients over
the course of a year (Nielsen and Butt, 1955: Appendix: Figure III). In both cases DMP
was shown to attenuate disease progression; however, the study was discontinued due to
the extensive formation of abscesses at the intramuscular injection sites and was
abandoned as a therapy due to inconsistencies with the theory of copper-induced HD
(Campbell et al., 1961). Today, DMP is still indicated for the treatment of heavy metal
poisoning, especially with arsenic, gold, mercury, and lead (Vilensky & Redman, 2003).
In a recent cell-based screen for FDA-approved compounds to treat Huntington’s disease,
DMP was found to elicit the highest degree of neuroprotection against mutant huntingtin
(mHTT)-induced toxicity (Aiken & Schweitzer, 2004). Upon further experimentation,
researchers found that DMP is a potent activator of Nrf2 (Pitts et al., 2012), which
suggests that the neuroprotective effects of DMP are derived, in part, from its ability to
elicit an intracellular antioxidant response. Interestingly, a previous study found that
DMP binds the same cysteine thiols in Keap1 as arsenic does (He & Ma, 2010). Several
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studies have shown that arsenic activates Nrf2 through the non-canonical mechanism by
promoting the autophagosomal degradation of Keap1 (Lau et al., 2013). This suggests
that DMP may be working via the non-canonical pathway (Figure 1, right). However, it is
still uncertain if DMP exerts its neuroprotective effects against mHTT-induced toxicity
exclusively by Nrf2 activation.

1.6

Hypothesis and Research Outline

The expression of mHTT has been shown to exacerbate intracellular oxidative stress by
interfering with Nrf2-dependent ARE-directed expression of cytoprotective genes in a
PC12 cell line capable of inducible expression of mHTT (Dailey, 2012). In addition,
DMP was found to be neuroprotective through the induction of Nrf2 activity and the
subsequent upregulation of cytoprotective and antioxidant genes (i.e., Prx1; Dailey, 2012;
Pitts et al., 2012). In this study it is hypothesized that the neuroprotective effects of DMP
are mediated via non-canonical Nrf2 activation. Experiments will be performed using
more clinically-relevant striatal cell lines derived from a knock-in transgenic mouse
expressing humanized Exon 1 of HTT with either 7 (STHdhQ7) or 111 (STHdhQ111) polyglutamine repeats, which will serve as wild-type and HD cell lines, respectively. The
mechanisms by which DMP exerts its effects will be examined by looking at changes in
whole cell protein levels, as well as the subcellular localization of key proteins: Nrf2,
Keap1, and p62.
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Figure 1

Figure 1. Proposed mechanism by which DMP promotes non-canonical activation of
Nrf2. Under basal cell conditions, Nrf2 is sequestered in the cytosol by its negative
regulator, Keap1, which forms a Cul3-dependent E3 ubiquitin ligase complex to facilitate
the poly-ubiquitynation and subsequent degradation via the 26S proteasome (top).
Canonical activation of Nrf2 occurs when ROS-triggered oxidation of thiol groups in
Keap1 promotes a conformational change resulting in the release of Nrf2. Nrf2 is no
longer targeted for proteasomal degradation and is then free to enter the nucleus where it
can bind to antioxidant response elements (AREs) and promote increased transcription of
antioxidant and cytoprotective genes (left). In the non-canonical pathway, Keap1 binds to
p62 and is targeted for degradation by the autophagosomal system, thereby releasing
Nrf2, which translocates into the nucleus. DMP may promote increased interaction
between Keap1 and p62, or help facilitate the targeting of these proteins to emerging
autophagosomes (right).
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Chapter 2 : Materials and Methods
2

Materials and Methods

2.1

Cell Culture

The experiments outlined in this study were performed in two immortalized striatal cell
lines derived from a knock-in transgenic mouse containing homozygous Huntingtin
(HTT) loci with a humanized Exon 1 with either 7 (STHdhQ7) or 111 (STHdhQ111) polyglutamine repeats. These two cell lines are representative of a wildtype or HD-afflicted
phenotype, respectively. Cells were incubated at 33°C and 5% CO2 and were maintained
in high glucose/high serum media (HH media: Dulbecco’s Modified Eagle Medium
(DMEM) containing 4.5g/L glucose and supplemented with 5% fetal bovine serum (FBS)
and 1% penicillin/streptomycin). During drug treatment studies the cells were cultured in
low/low media (LL media: DMEM containing 1g/L glucose and supplemented with 1%
FBS and 1% penicillin/streptomycin) to ensure that the potentially protective effects of
the serum metabolites did not confound the results. Due to the ability of STHdhQ111 cells
to survive and proliferate in the presence of mHTT, both cell lines were stressed with the
mitochondrial complex II inhibitor, 3-NP, in order to assess the protective effects of
DMP.
Later experiments were also performed on mouse hippocampal HT22 cells, which served
as the transfection-tolerant cell line. HT22 cells were incubated at 37°C and 5% CO2 and
were maintained in DMEM containing 4.5g/L glucose and supplemented with 10% FBS,
and 1% penicillin/streptomycin.

2.2

Subcellular Fractionation and Immunoblot Analysis

For nuclear fractionation, cells were rinsed with 1x Dulbecco’s Phosphate Buffered
Saline (DPBS), trypsinized with TrypLE™ Express Enzyme and centrifuged at 1.5 rpm
for 5 minutes. The supernatant was discarded and cells were resuspended in hypotonic
lysis buffer (20mM Tris (pH 7.4), 10mM NaCl, 3mM MgCl2, 1mM PMSF, protease
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inhibitor) and incubated on ice for 15 minutes. Cells were then lysed using 10% NP-40 in
dH2O,

and centrifuged at 4°C at 6000g for 5 minutes. The cytosolic fraction (supernatant)

was transferred to another vial. The nuclear pellet was rinsed twice in hypotonic lysis
buffer containing 1% NP-40 and then resuspended in SDS lysis buffer (50mM Tris (pH
7.5), 2% SDS, 1mM PMSF, protease inhibitors) and sonicated. Harvested protein
concentrations were quantified by Lowry assay using a colourimetric DC™ Protein
Assay Kit (BioRad). Protein extracts were then reduced in loading buffer containing
100mM dithiothreitol (DTT) and 2% β-mercaptoethanol (BME) and boiled for 5 minutes.
The samples were resolved by SDS-PAGE on a 12% polyacrylamide gel using a MiniPROTEAN® gel electrophoresis apparatus, and transferred onto a polyvinylidine fluoride
(PVDF) membrane via electroblotting overnight at 4°C. The PVDF membrane was rinsed
in Tris-buffered saline containing 1% Tween-20 (TBS-T), incubated in blocking solution
(TBS-T + 3% bovine serum albumin, 1% milk powder) for a minimum of one hour at
room temperature, rinsed again with TBS-T, and then probed with a primary antibody
overnight at 4°C. The following primary antibodies were used for immunoblot analysis in
this study: polyclonal rabbit anti-Nrf2 (Santa Cruz Biotechnology), polyclonal rabbit
anti-Keap1 (ProteinTech), polyclonal rabbit anti-Prx-1 (AbFrontier), polyclonal rabbit
anti-p62 (Cell Signaling), polyclonal rabbit anti-GAPDH (IMGENEX), and polyclonal
rabbit anti-Histone H3 (Cell Signaling Technology),
The following day, PVDF membranes were rinsed with TBS-T and incubated in blocking
solution containing the appropriate secondary antibody (1:10000 dilution) at room
temperature for one hour. The following secondary antibodies were used for immunoblot
analysis in this study: blotting grade goat anti-rabbit IgG (H+L) Horseradish Peroxidase
Conjugate 170-6515 (BioRad, Hercules, CA, USA) and blotting grade goat anti-mouse
IgG (H+L) Horseradish Peroxidase Conjugate 170-6516 (BioRad, Hercules, CA, USA).
Membranes were then rinsed again with TBS-T and developed using SuperSignal® West
Pico Chemiluminescent Substrate (Thermo Scientific). Protein signal was detected by
Molecular Imager® ChemiDoc™ XRS System (BioRad), and densitometric analyses
were performed using ImageJ software. Band densities were standardized against the
loading control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
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2.3

Immunofluorescence Microscopy

Glass coverslips (18mm) were autoclaved and coated with poly-D-lysine (50µg/mL) in a
12-well plate for at least 3 hours and were then rinsed with dH2O and allowed to dry
completely. Both cell lines were seeded at the same density and incubated at 33°C
overnight. The following day cells were treated with vehicle, 10mM 3-NP, 10µM DMP,
or both 3-NP and DMP for 24 hours. For experiments in which immunofluorescence was
performed on ectopically expressed Nrf2, cells first underwent a transient transfection: in
line with standard transfection protocol, 5µg of the Nrf2-Flag plasmid was added to 8µL
of Lipofectamine 2000 (Invitrogen) in 1mL of Opti-MEM I transfection media
(Invitrogen). This was added to both STHdhQ7 and STHdhQ111 cells, which were then
incubated in the transfection reagents at 33°C for 6 hours. After incubation, the
transfection reagents were replaced with HH media and cells were left to recover
overnight at 33°C. The morning following transfection, HH media was replaced with LL
media, and the cells were treated as per previously described that afternoon. Afterward 24
hours the cells were rinsed with DPBS and then fixed with 4% paraformaldehyde in
DPBS for 10 minutes. They were then washed with DPBS for 5 minutes, followed by two
5-minute washes with DPBS containing 0.1% Triton-X (PBS-T). Cells were incubated in
blocking solution (PBS-T + 4% goat serum) overnight at 4°C. Coverslips were then
placed cell-side down on top of a 50µl drop of primary antibody in PBS-T + 3% goat
serum for a minimum of 2 hours in a humidity chamber at room temperature to limit
evaporation. The following primary antibodies were used for immunofluorescence
staining in this study: polyclonal rabbit anti-Nrf2 (Santa Cruz Biotechnology),
monoclonal mouse anti-Keap1 (ThermoFisher Scientific), polyclonal rabbit anti-Keap1
(ProteinTech), and monoclonal mouse anti-Flag (Sigma Aldrich). Following incubation
they were placed back into the 12-well plate and rinsed with PBS-T, followed by a 45minute incubation period in appropriate secondary antibody in PBS-T + 3% goat serum.
The following secondary antibodies were used for immunofluorescence staining in this
study: goat anti-rabbit IgG (H+L) Alexa Fluor® 647 (Life Technologies), and goat antimouse IgG (H+L) Alexa Fluor® 488 (Life Technologies). The coverslips were
subsequently replaced into the 12-well plate, rinsed with PBS-T, mounted onto glass
slides using ProLong® Gold Antifade Reagent with the nuclear stain 4’,6-Diamidino-2-
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phenylindole (DAPI), and sealed with nail polish. Slides were imaged using either a
Leica DM6000 M widefield fluorescent microscope or an Olympus FluoView™ FV1000
confocal microscope. Images were taken from five random locations on each slide, and
exposure times were kept constant across all treatment groups. Fluorescence intensity and
area values were obtained from every cell in each image using ImageJ software, and the
mean values were averaged across at least three independent experiments. Statistical
analyses were performed by a one-way analysis of variance (ANOVA) test, and post-hoc
Tukey’s test.

2.4

Trypan Blue Exclusion Test

The effects of 3-NP treatment (10mM) with or without DMP treatment (10µM) on cell
viability were assessed by trypan blue exclusion test: both cell lines (STHdh Q7 and
STHdh Q111) were seeded in triplicate at the same density in 12-well plates and were
incubated overnight to ensure cell adherence. The following day, cells received one of the
following treatments: untreated, 3-NP alone, DMP alone, or treated with DMP one hour
prior to 3-NP treatment. The cells were incubated for either 24 or 48 hours following the
3-NP treatment, at which point the cell media for each well (containing detached, dead
cells) was collected separately and the cells were trypsinized using 150µl of TrypLE
Express and incubated at 33°C for 5 minutes. Next, cells from each well were
resuspended with their respective media aliquots, placed into a 15mL conical tube, and
centrifuged at 500x g for 5 minutes. Most of the supernatant was then aspirated, and the
cell pellet was resuspended in 150µl of media. An equal volume of trypan blue dye was
added to the cell suspension, which was then mixed and loaded into a hemocytometer for
counting. Viable cells excluded the dye and appeared white, whereas dead cells took up
the dye and appeared blue. Counts were performed blindly and cell viability was
calculated as the number of white cells over the total number of cells counted in each
sample, averaged for every treatment group. Statistical analyses were performed by a
one-way analysis of variance (ANOVA) test, and post-hoc Tukey’s test.
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2.5

MTT Assay

To assess the influence of DMP on cytotoxicity after inducing oxidative stress, an MTT
colourimetric assay was performed. NADH- or NADPH-dependent enzymes in the
mitochondria of viable cells are able to reduce the yellow tetrazolium dye, MTT, to form
insoluble purple formazan crystals. The crystals are subsequently dissolved in a non-polar
solvent to form a coloured solution, the absorbance of which can be quantified by
spectrophotometry. Because non-viable cells cannot reduce MTT to formazan, the degree
of light absorption is indicative of the number of live cells. Both cell lines (STHdhQ7 and
STHdhQ111) were cultured in LL media and were seeded in quadruplicate at the same
density in 96-well plates. Cells were incubated overnight at 33°C. The next day cells
received one of the following pre-treatments: media only (no treatment), or 10µM DMP.
One hour after pre-treatment each plate received a treatment of either media only (no
treatment) or 10mM 3-NP. At 24 and 48 hours, cells were rinsed once with 100µL of LL
media to remove all traces of the treatment drugs, which might interfere with the MTT
assay, and fresh LL media was added to each well. Next, 10µL of MTT solution
(1mg/mL) was added to each well at a 1:10 dilution, and the plate was incubated for 3
hours (33°C, 5% CO2). The media containing the MTT solution was then aspirated and
replaced with 100µL of DMSO and the plate was left to rock overnight at room
temperature. The following day absorbances were read at 570nm with a reference filter at
690nm, using the Tecan Infinite® M1000 PRO plate reader. Statistical analyses were
performed by a one-way analysis of variance (ANOVA) test, and post-hoc Tukey’s test.

2.6

Live/Dead Cell Viability/Toxicity Assay

The effects of 3-NP, with or without pre-treatment with DMP, on cell viability was
further assessed using the LIVE/DEAD® Viability/Cytotoxicity Kit, for mammalian cells
(LifeTechnologies), which utilizes the calcein AM probe to assess cell viability. Calcein
AM is a fluorogenic esterase substrate that can be hydrolyzed by viable cells to a green
fluorescent product (calcein); therefore the intensity of green fluorescence is correlated
with the amount of cells with intact membranes and esterase activity and, thus, viability.
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Both cell lines (STHdhQ7 and STHdhQ111) were cultured in LL media and were seeded in
quadruplicate at the same density in opaque-welled, glass-bottomed 96-well plates. Cells
were incubated overnight at 33°C. The following day cells received one of the following
pre-treatments: media only (no treatment), or 10µM DMP. One hour after pre-treatment
each plate received a treatment of either media only (no treatment) or 10mM 3-NP for 24
or 48 hours. Next, media was aspirated and cells were incubated in DPBS containing
calcein AM at room temperature for 40 minutes. Next, fluorescence data were obtained
by exciting the florophores at 485nm and reading the emissions at 530nm using the Tecan
Infinite® M1000 PRO plate reader and analyzed using Magellan™ data analysis
software. Statistical analyses were performed by a one-way analysis of variance
(ANOVA) test, and post-hoc Tukey’s test.

2.7

Mitochondrial ROS Quantification

Mitochondrial ROS levels were visualized in both STHdhQ7 and STHdhQ111 using the
fluorescent dye MitoTracker Red CM-H2-XRos (MTR; Invitrogen). MTR is a nonfluorescent reduced dye that specifically localizes to mitochondria in live cells and
fluoresces upon oxidation. An increase in fluorescence intensity is indicative of elevated
mitochondrial ROS levels. Cells were seeded in LL media in 35mm plastic cell culture
dishes and incubated at 33°C overnight. Then cells received one of the following pretreatments: vehicle only (no treatment), or 10µM DMP. One hour after pre-treatment,
each plate received a treatment of either vehicle only (no treatment), or 10mM 3-NP for
24 hours. Next, media was aspirated and replaced with media containing 200nM MTR
and incubated at 33°C for 30 minutes. Cells were rinsed with pre-warmed DPBS and then
incubated in DPBS containing 10µg/mL Hoescht stain for another 20 minutes. After this
cells were rinsed twice with pre-warmed DPBS and placed in phenol red-free LL media
and visualized by fluorescence microscopy (Zeiss AxioObserver, 400x magnification).
Images were taken from 5 random fields of view in each plate using a Q Imaging (Retiga
1300 monochrome 10-bit) camera with Q Capture software. MTR was quantified by
calculating average fluorescence intensity per unit area with ImageJ software. Statistical
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analyses were performed by a one-way analysis of variance (ANOVA) test, and post-hoc
Tukey’s test.

2.8

Transfection of Keap1-RFP and Nrf2-GFP Vectors

STHdhQ7 and STHdhQ111 cells were seeded on a glass bottom 6-well dish, which had been
previously treated with poly-D-lysine (50µg/mL) for 3 hours and then rinsed with dH2O
and allowed to dry completely. Exactly 2.5µg of Keap1-RFP and 2.5µg of Nrf2-GFP
plasmids were added to 8µL of Lipofectamine 2000 (Invitrogen) in 1mL of Opti-MEM I
transfection media (Invitrogen), and added to adhered striatal cells, which were then
incubated in the transfection reagents at 33°C for 6 hours. After incubation, the
transfection reagents were replaced with HH media and cells were left to recover
overnight at 33°C. The morning following transfection, HH media was replaced with LL
media, and the cells received one of the following treatments: no treatment (control),
10mM 3-NP, or 10mM 3-NP and 10µM DMP. The dish was then placed in a Chamlide
stage-top incubator on a Leica DM6000 M widefield fluorescent microscope and
fluorescent images were captured every 15 minutes for 6 hours using a Hamamatsu Orca
digital camera equipped with Metamorph software.
HT22 cells underwent the same procedure outlined above, except that they were singly
transfected with 5µg Keap1-RFP with 8µl Lipofectamine 2000.
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Chapter 3 : Results
3
3.1

DMP confers neuroprotection against 3-NP-induced cytotoxicity
in striatal cell lines expressing full-length normal and
polyglutamine-expanded huntingtin

Previous studies have revealed that treatment with DMP elicits neuroprotection against
cytotoxicity associated with the expression of mutant huntingtin (mHTT), likely through
the activation of Nrf2 and subsequent upregulation of protective genes (i.e., Prx-1;
Dailey, 2012). However, this has not been previously reported in the striatal cell lines,
which express a humanized form of exon 1 of the huntingtin protein. Therefore, the first
step was to assess the degree of neuroprotection elicited by DMP on striatal cells
expressing either the normal or polyglutamine-expanded huntingtin protein (STHdhQ7
and STHdhQ111, respectively). A number of cell viability assays were performed to
determine the effects of 10µM DMP on cytotoxicity induced by treatment of STHdhQ7
and STHdhQ111 with 10mM 3-NP for 24 and 48 hours by using the live/dead cell viability
assay, MTT assay, and trypan blue exclusion assay (Figures 2A- C, respectively). Cell
viability determined by the live/dead assay, which is a more sensitive test of viability,
revealed a significant increase (p < 0.05) in viability of STHdhQ7 at 24 and 48 hours, and
STHdhQ111 at 48 hours following pre-treatment with DMP when compared to those
treated with 3-NP alone (Figure 2A). Cell viabilities determined by both MTT assay and
trypan blue exclusion assay follow a similar trend; however, these results were not
significant (Figures 2B, C). Due to the variability in sensitivity that occurs in these cell
lines at different passage numbers, these assays may have required a larger number of
replicates. DMP also appears to preserve the overall morphology and proliferative
abilities of STHdhQ111 cells, which is compromised following 3-NP treatment (Figure
2D).
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Figure 2

Figure 2. DMP confers neuroprotection against 3-NP-induced cytotoxicity in both
STHdhQ7 and STHdhQ111 cell lines at 48 hours. Relative cell viability determined by
(A) LIVE/DEAD Cell Viability® assay, (B) MTT assay, and (C) Trypan Blue assay of
STHdhQ7 and STHdhQ111 cell lines grown at 33°C, treated with 10mM 3-NP and/or 10µM
DMP for 24 and 48 hours. Signals obtained from the control conditions for each cell line
were set as 100% viability, and the other treatment viabilities were calculated
accordingly. Error bars depict standard error of the mean derived from at least three
independent experiments (*, p < 0.05). (D) Light microscopy images of STHdhQ111 cells
following treatment with 10mM 3-NP and/or 10µM DMP for 24 hours.
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3.2

DMP treatment ameliorates the 3-NP-induced increase in
mitochondrial ROS levels in STHdhQ111 cells

3-NP is an inhibitor of complex II in the mitochondrial electron transport chain, which
leads to increased ROS production. To confirm that the cytoprotective effects of DMP are
exerted through an antioxidant mechanism, mitochondrial ROS levels were assessed in
live striatal cells following treatment with DMP under basal and stressed conditions. Both
STHdhQ7 and STHdhQ111 were stained with MitoTracker Red CM-H2Xros (MTR)
following a 24-hour treatment with the mitochondrial toxin 3-NP with or without DMP
pre-treatment. Cells were then imaged by fluorescence microscopy (400x magnification;
Figure 3A). Quantification of MTR fluorescence intensity revealed a significant increase
of approximately 60% (p < 0.01) in STHdhQ111 cells treated with 3-NP compared to
STHdhQ111 cells under control conditions (Figure 7B). This was not observed in the
STHdhQ7 cell line. Furthermore, in the STHdhQ111 cell line, the increase in mitochondrial
ROS induced by 3-NP treatment was significantly reduced by pre-treatment with DMP (p
< 0.001; Figure 3B).
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Figure 3
A)
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B)

Figure 3. Pre-treatment with DMP protects against 3-NP-induced mitochondrial
insult by reducing the levels of ROS in STHdhQ111 cells. (A) Mitochondrial reactive
oxygen species (ROS) levels were measured as fluorescence intensity after staining
STHdhQ7 and STHdhQ111 with the red fluorescent dye MitoTracker Red CM-H2Xros
(MTR). STHdhQ111 cells exhibited an elevated response to 24-hour treatment with 10mM
3-NP compared to control conditions in STHdhQ111 as well as 3-NP-treated STHdhQ7
cells. This increase was rescued by pre-treatment with 10µM DMP. Nuclei were stained
blue with Hoescht and cells were observed by fluorescence microscopy at 400x
magnification. (B) Quantification of MTR fluorescence revealed a significant decrease in
STHdhQ111 cells that were treated with 10µM DMP prior to 3-NP treatment (p < 0.001).
STHdhQ7 cells exhibited a similar trend in MTR fluorescence. Error bars represent
standard error of the mean derived from three independent experiments.
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3.3

DMP does not activate Nrf2 by decreasing the protein levels of its
negative regulator, Keap1

In order to assess whether DMP was reducing oxidative stress by activating Nrf2 via the
proposed autophagosomal degradation of Keap1, and also to determine whether DMP
elicited changes in Nrf2 accumulation and downstream protein expression, whole cell
lysates from STHdhQ7 and STHdhQ111 cells treated with or without 10mM 3-NP and
10µM DMP for 24 hours were analyzed by western blotting, using primary antibodies
specific to Keap1, and Nrf2, as well as two downstream transcriptional targets of Nrf2:
p62, and Prx-1. Antibodies specific to GAPDH were used as the loading control (Figure
4A). Contrary to what was hypothesized, neither Nrf2 nor Keap1 overall protein levels
were significantly affected by treatment with DMP in either cell line (Figures 4B, C).
Interestingly, however, immunoblot analysis detected a high molecular weight Keap1
immunoreactive band in the STHdhQ111 cells treated with 3-NP alone, which was not
evident when the cells were also treated with DMP (Figure 4A, arrowhead). In 3-NPtreated STHdhQ111 cells, protein levels of p62 and Prx-1 increased modestly following
pre-treatment with DMP by 40% and 30% on average, respectively (Figures 4D, E);
however, due to the great variability of protein expression levels in these cell lines across
experiments, these figures were not significant.
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Figure 4. Western blot analysis of protein expression levels in STHdhQ7 and
STHdhQ111 cells.

(A) Immunoblot analysis of STHdhQ7 and STHdhQ111 whole cell

lysates revealed that DMP does not significantly affect overall Nrf2 or Keap1 protein
levels. Protein levels of both p62 and Prx-1 appear to be elevated following treatment of
STHdhQ111 with DMP. Arrowhead denotes high molecular weight Keap1 immunoreactive
band present only in 3-NP-treated STHdhQ111 cells. (B – E) Densitometric analyses
revealed no significant impact of DMP on protein levels of any of the proteins examined.
Protein levels of GAPDH were used as a loading control. Error bars represent standard
error of the mean derived from three independent experiments.
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3.4

DMP promotes the nuclear translocation of Nrf2

Although DMP does not appear to impact overall protein levels of Keap1 or Nrf2, studies
have shown that a number of Nrf2 activators merely facilitate the nuclear translocation of
Nrf2, thereby increasing its activity (Jain et al., 2005). Thus, the next step was to perform
a nuclear fractionation followed by immunoblot analysis to determine if DMP acts by
promoting the nuclear translocation of Nrf2. Subcellular fractionation of STHdhQ7 and
STHdhQ111 cells was performed to isolate cytosolic and nuclear protein extracts, which
were then screened by immunoblotting using primary antibodies for Nrf2, Keap1, and
p62. As expected, STHdhQ7 cells exhibited a moderate decrease in cytosolic Nrf2 and a
corresponding increase of nuclear Nrf2 following treatment with 3-NP; however this was
not observed in the STHdhQ111 cell lines, which actually exhibited a substantial decrease
in cytosolic Nrf2 with no change in nuclear Nrf2 levels (Figures 5A and 5B). Following
treatment with DMP, however, STHdhQ111 cells did exhibit higher nuclear Nrf2 levels,
and this persisted even when cells were then treated with 3-NP (Figures 5A and 5B). The
subcellular localization of neither Keap1 nor p62 appeared to be affected by treatment
with DMP (Figures 5A and 5B). Densitometric analysis revealed a trend showing that
nuclear Nrf2 levels were indeed increased following DMP treatment in STHdhQ111 cells,
although these numbers are not significant. A number of time-consuming modifications
had to be made to optimize the antibody and fractionation protocol in order to detect the
low levels of Nrf2, which is why the values shown for Nrf2 are derived from one
experiment (Figure 5C). Analysis of Keap1 and p62 levels revealed no significant change
in subcellular localization in neither STHdhQ7 nor STHdhQ111 cells (Figures 5D, 5E). Due
to the high variability in protein expression levels in these cell lines, even under control
conditions, a larger number of replicates will be required to solidify these findings.
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Figure 5. Western blot analysis of cytosolic and nuclear proteins in STHdhQ7 and
STHdhQ111 cells. Immunoblot analysis of (A) cytosolic and (B) nuclear proteins in both
STHdhQ7 and STHdhQ111 cells following 24 hours of treatment with 10mM 3-NP, with or
without 10µM DMP pre-treatment revealed an increase in nuclear Nrf2 levels of
STHdhQ111 cells following DMP treatment. (C) Densitometric analysis of Nrf2 showing
an insignificant trend toward increasing nuclear Nrf2 levels following DMP treatment.
Due to technical difficulties and time constraints, values for Nrf2 protein levels are
derived from only one experiment. (D and E) Densitometric analyses of Keap1 and p62
protein levels, respectively, reveal substantial variability across treatment groups, with no
significant changes following DMP treatment. Error bars represent standard error of the
mean derived from three independent experiments.
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3.5

DMP promotes the nuclear localization of exogenous Nrf2, while
reducing the number of Keap1-positive puncta

Since Nrf2 is maintained at such low levels in these cells, an over-expression construct
was used for easier detection. STHdhQ7 and STHdhQ111 cells were transfected with Nrf2Flag and underwent 24 hours of treatment with vehicle, 10mM 3-NP, 10µM DMP, or
both 3-NP and DMP. The cells were then fixed for immunofluorescence staining with
anti-Keap1 and anti-Flag antibodies and visualized by widefield fluorescence
microscopy. Images were taken at 400x magnification (Figure 6). Nrf2 was found
primarily in the nucleus across all treatment groups in the STHdhQ7 control cell line
(Figure 6A). However, in the STHdhQ111 mutant cell line (Figure 6B), Nrf2 was found in
both the nucleus as well as diffusely throughout the cytoplasm under basal conditions as
well as following treatment with 3-NP. After treatment with DMP, however, Nrf2
appeared to be more concentrated in the nucleus. In addition, Keap1-positive inclusion
bodies were detected in the cytosol (arrows) and nucleus (arrow head), under basal and
stress-only conditions in the mutant line, but not in the control line (Figure 6B).
Unfortunately, due to challenges associated with poor transfection efficiency and posttransfection hypersensitivity, these findings were unable to be replicated.
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Figure 6
A)

35

B)
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Figure 6. DMP exposure promotes increased Nrf2 nuclear localization and prevents
formation of cytoplasmic and nuclear inclusions containing Keap1 in STHdhQ111
cells. (A) STHdhQ7 and (B) STHdhQ111 cells were transfected with an Nrf2-Flag
expression construct followed by immunofluorescence staining with anti-Flag and antiKeap1 antibodies. Ectopically expressed Nrf2 was found primarily in the nucleus of
STHdhQ7 cells under all treatment conditions. In contrast, ectopically expressed Nrf2 was
found in both the cytoplasm and nucleus of SThdhQ111 cell under both basal conditions
and following treatment with 10mM 3-NP. Treatment with 10µM DMP promoted
increased Nrf2 nuclear localization. DMP exposure reduced the formation of Keap1positive cytoplasmic (arrows) and nuclear (arrow head) inclusion bodies in STHdhQ111
cells.
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3.6

DMP promotes the up-regulation and nuclear translocation of
endogenous Nrf2

To further verify that DMP increases nuclear localization of Nrf2, and to accurately
compare protein expression levels between treatment groups and cell lines, STHdhQ7 and
STHdhQ111

cells

underwent

an

identical

treatment

protocol

followed

by

immunofluorescence staining to detect endogenous Nrf2 and Keap1 proteins. Cells were
visualized by confocal fluorescence microscopy to allow for more accurate Nrf2
detection even at low expression levels, and images were taken using an immersion oil
objective at 400x magnification. STHdhQ111 cells exhibit a drastic decrease in both Nrf2
and Keap1 fluorescence intensities following treatment with 3-NP, which is rescued with
DMP pre-treatment (Figure 7A). Quantification of fluorescence intensity in 3-NP-treated
STHdhQ111 cells revealed a two-fold increase in Nrf2 fluorescence following DMP
treatment, as well as an increase of Keap1 fluorescence intensity of 50% on average;
however, due to the variability across experiments, these values were not significant (p >
0.05; Figure 7B).
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Figure 7
A)
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B)
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C)

D)

Figure 7. DMP promotes the upregulation and nuclear localization of Nrf2. (A)
STHdhQ7 and (B) STHdhQ111 cells were treated with 10mM 3-NP, 10µM DMP, or both
for 24 hours, at which point they were fixed and immunostained with anti-Keap1 and
anti-Nrf2 antibodies, with nuclei counterstained by DAPI, and imaged via confocal
microscopy (Scale bar = 50µm). (C, D) Quantification of fluorescence levels for
endogenous Nrf2 (left) and Keap1 (right) relative to STHdhQ7 control revealed a trend
towards an increase in both Nrf2 and Keap1 fluorescence following treatment with DMP,
both with and without 3-NP treatment. Error bars represent the standard error of the mean
derived from five independent experiments.
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3.7

DMP treatment prevents the 3-NP-induced formation of
cytoplasmic puncta containing Nrf2 and Keap1 in STHdhQ111 cells

To visualize the interaction of Nrf2 and Keap1 in real time, STHdhQ111 cells were cotransfected with Nrf2-GFP and Keap1-RFP expression plasmids and treated with 10mM
3-NP, or both 10mM 3-NP and 10µM DMP. They were then placed in a stage-top
incubator and visualized by time-lapse widefield fluorescence microscopy. Images were
captured at 400x magnification every 15 minutes for 24 hours (Figure 8). Expression of
Keap1-RFP resulted in the formation of cytoplasmic inclusion bodies that, in some cells,
co-localized with Nrf2-GFP (Figure 8, arrows). The formation of cytoplasmic aggregates
containing both Keap1-RFP and Nrf2-GFP was prevented by DMP exposure. Due to the
heightened sensitivity to toxins experienced by STHdhQ111 cells following transfection,
no cells remained alive after 3 hours in the 3-NP-treated group. Unfortunately, due to
challenges

associated

with

poor

transfection

efficiency

hypersensitivity, these findings were unable to be replicated.

and

post-transfection
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Figure 8

Figure 8. Timelapse fluorescence microscopy reveals formation of cytoplasmic
puncta containing both Keap1-RFP and Nrf2-GFP in 3-NP-exposed STHdhQ111
cells. STHdhQ111 cells were co-transfected with plasmids encoding Keap1-RFP and Nrf2GFP and then treated with 10mM 3-NP (left two panels) or with both 10mM 3-NP and
10µM DMP (right two panels) and then imaged by widefield fluorescence microscopy
(400x magnification). The formation of cytoplasmic puncta containing both Keap1-RFP
and Nrf2-GFP (arrows) was prevented by DMP treatment.
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3.8

Cytotoxic over-expression of Keap1-RFP can be rescued with
DMP treatment in HT22 cells

Due to the poor transfection efficiency and post-transfection survival of STHdhQ111 cells,
the Keap1-RFP vector was transfected into a more resilient hippocampal cell line (HT22
cells). Cells were then placed in a stage-top incubator, treated with 100µM DMP and
visualized by time-lapse widefield fluorescence microscopy. Images were taken every 15
minutes at 400x magnification (Figure 9). The time-lapse images at 0.5 hours (Figure 9
A) and 4.25 hours (Figure 9 B) of ectopically expressed Keap1-RFP in HT22 cells
revealed the progressive accumulation of Keap1-RFP in puncta that formed shortly
before cell death. In contrast, DMP treatment directed Keap1-RFP to small vesicle-like
structures; an event associated with decreased levels of Keap1 and increased cell
survival. Unfortunately, there was not enough time to complete replicates of this
experiment, and these findings are derived from a single experiment.
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Figure 9
A)
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B)

Figure 9. Overexpression of Keap1-RFP leads to the formation of puncta. Timelapse fluorescence imaging at 0 hours (A) and 4.25 hours (B) of ectopically expressed
Keap1-RFP in HT22 cells revealed the progressive accumulation of Keap1-RFP in
puncta (arrows), whose formation strongly correlated with subsequent cell death.
Treatment of cells with DMP (100µM) directed Keap1-RFP to small vesicle-like
structures and overall decreased fluorescence. Top panels show overlay of DIC and
fluorescent micrographs.
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Chapter 4 : Discussion
4
4.1

Overview

Previous studies have provided compelling evidence for the role for antioxidants in
treating the oxidative stress-induced pathogenesis of many neurodegenerative disorders,
including Huntington’s disease (HD; Browne and Beal, 2006). Furthermore, although
canonical activators of Nrf2 have been examined extensively, this investigation sought to
characterize the mechanisms and neuroprotective potential of a non-canonical Nrf2
activator. The findings of this study suggest that DMP plays a role in reducing oxidative
stress thereby mediating resistance to 3-NP and mHTT-induced neurotoxicity in a striatal
cell model of HD. Additionally, the neuroprotective nature of DMP did appear to be
mediated in part by increased Nrf2 nuclear translocation and activation. Furthermore,
DMP does not seem to be activating Nrf2 through the hypothesized non-canonical
autophagy pathway, but perhaps through a more novel mechanism.

4.2

DMP confers neuroprotection against 3-NP by reducing
mitochondrial ROS levels and oxidative damage-induced
neurotoxicity

3-NP is an irreversible complex II inhibitor in the mitochondrial ETC, and when it is
administered to rodents in their drinking water, it causes targeted lesions in the striatum,
producing symptoms reminiscent of HD (Borlongan et al., 1997). It has also been shown
that mitochondrial complex II inhibitors generate ROS by disrupting the ETC (PérezSeveriano et al., 2004). STHdhQ111 cells have a heightened sensitivity to 3-NP compared
to the wild-type STHdhQ7 cells, owing potentially to their compromised antioxidant
defense systems. Cell viability of both striatal cell lines was assessed following treatment
with 10mM 3-NP for 24 and 48 hours with or without pre-treatment with 10µM DMP.
The findings from both MTT (Figure 2B) and Trypan Blue Exclusion (Figure 2C) assays
in this study did not yield significant results in line with previous reports (Pitts et al.,
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2012). However, further analysis of cell viability by a more sensitive technique, the
LIVE/DEAD Cell Viability/Cytotoxicity assay (Figure 2A), did reveal a significant
increase in cell survival in DMP-pre-treated striatal cells (Figure 2A). It is likely that, due
to the changes in cell behavior that occur at different striatal cell passage numbers, the
variability in toxin sensitivity is high enough that crude tests such as the trypan blue
exclusion assay are unable to accurately report the relative number of viable cells.
Furthermore, although cells were rinsed twice in an effort to remove all traces of
treatment drug, it is possible that residual 3-NP interfered with the MTT assay, thus
confounding the results. In addition, this study found that DMP mediated protection
against mHTT- and 3-NP-induced neurotoxicity correlated with a decrease in
mitochondrial ROS levels. Following treatment with 10mM 3-NP, STHdhQ111 cells
exhibited a significant increase in MTR fluorescence intensity, which was ameliorated in
DMP-pre-treated cells (Figure 3). In contrast, STHdhQ7 control cells under the same
treatment conditions did not show increased mitochondrial ROS following 3-NP
treatment. Therefore, these results taken together indicate that DMP may elicit
neuroprotection by reducing the levels of mitochondrial ROS and thus the extent of
oxidative damage caused by 3-NP.

4.3

DMP increases nuclear Nrf2 protein levels

The Nrf2-Keap1-ARE pathway is a redox-sensitive signaling axis, which regulates the
expression of a wide variety of cytoprotective proteins and phase II detoxifying enzymes
to protect the cell against oxidative stress, and harmful toxins. Under basal conditions,
Nrf2 is maintained at very low levels in the cell due to contant proteosomal degradation.
Nrf2 levels fluctuate in rapid response to the changing intracellular environment, which
allows it to translocate to the nucleus and increase expression of these protective genes in
order to preserve redox homeostasis in mammalian cells. However, previous studies have
reported Nrf2 dysregulation in a number of neurodegenerative diseases (Ramsey et al.,
2007), and even more have established the link between elevated ROS and
neurodegenerative disease (Berlett and Stadtman, 1997; Butterfield and Kanski, 2001;
Mariani et al., 2005). In addition, Nrf2 nuclear translocation deficits have been reported
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in other trinucleotide repeat neurodegenerative disorders such as Friedrich’s ataxia
(Paupe et al., 2009). Classical, or canonical, activators of Nrf2 mimic a transient
oxidative insult by modifying specific Keap1 cysteine residues, leading to the
dissociation and stabilization of Nrf2. This allows Nrf2 protein levels to increase within
the cell, which promotes Nrf2 nuclear localization where it dimerizes with small Maf
proteins and binds to the cis-acting regulatory element known as the antioxidant response
element (ARE; He and Ma, 2010).
A previous graduate student in the Cumming lab provided evidence, via the AREluciferase assay, that DMP activates Nrf2 and increases ARE-directed gene expression in
an mHTT-inducible PC12 model of HD (Dailey, 2012). Unfortunately, due to challenges
associated with poor transfection efficiency using the appropriate vectors, as well as
heightened toxin sensitivity post-transfection, this experiment could not be replicated in
the striatal cell lines. However, preliminary results from immunoblot analysis of nuclear
fractionation experiments, as well as immunofluorescence studies of both exogenous and
endogenous Nrf2 suggest that treatment with DMP promotes a modest nuclear
accumulation of Nrf2, which persists in the presence of the mitochondrial stressor, 3-NP
(Figures 5, 6, 7). Regrettably, the values presented for the immunoblot analysis of Nrf2
levels in subcellular fractions are derived from only one experiment. This is partially
attributable to the number of changes that had to be made to optimize the fractionation
protocol. Additionally, due to the extremely low levels of basal Nrf2 in the striatal cell
lines, the ongoing controversy as to the correct molecular weight and which antibodies to
use, as well as the high sensitivity of STHdhQ111 cells to 3-NP, it was a challenge to
detect Nrf2 following cell fractionation (Lau et al., 2013). Therefore, additional replicates
will need to be conducted using the appropriate protocols and antibodies in order to
solidify these findings. In order to solidify the claim that DMP activates Nrf2 in these
striatal cell lines, further studies should be completed in which transcriptional activity of
Nrf2 is more accurately assessed: either through modifications to the ARE-luciferase
assay, by using an Nrf2 Transcription Factor Assay Kit (Cayman Chemicals), or,
alternatively, via quantitative real-time polymerase chain reaction of downstream Nrf2
target proteins (such as Prx-1), performed both with and without DMP treatment.
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More recently, evidence has accumulated supporting an alternative model of Nrf2-Keap1
signaling: in this proposed model, newly translated Nrf2 translocates into the nucleus and
binds the ARE to maintain basal expression cytoprotective proteins. Afterwards, Nrf2
dissociates from the ARE and binds with nuclear Keap1, which facilitates the polyubiquitylation and subsequent nucleocytoplasmic shuttling of Nrf2 to the cytosol for
degradation via the 26 S proteasome (Nguyen et al., 2005). Cell culture studies have
revealed that the nucleocytoplasmic properties of Keap1 act via the Chromosomal
Maintenance (CRM1)/Exportin1 pathway, and the inhibition of this pathway leads to an
accumulation of nuclear Keap1 and a decrease in Nrf2 activity (Karapetian et al., 2005).
Experiments using an over-expression Keap1 vector and the CRM1/Exportin inhibitor,
Leptomycin B (LMB), showed that canonical Nrf2 activator tert-butylhydroquinone
(tBHQ) did not interfere with Keap1’s ability to enter the nucleus, which is thought to
involve the nuclear import protein, p65 (Nguyen et al., 2005; Yu et al., 2011).
Interestingly, the researchers that reported these findings also revealed that the
fluctuations in Keap1 and Nrf2 protein levels were so minute that they could not be
detected without using overexpression constructs as well as import inhibitors and
proteasomal inhibitors, respectively (Nguyen et al., 2005). Future studies should
investigate whether DMP activates Nrf2 through this novel pathway, perhaps by
interfering with the translocation of Keap1 into the nucleus, or by inhibiting the binding
of nuclear Keap1 to Nrf2 (Figure 10). This could be observed by using Keap1
overexpression constructs in a more transfection-tolerant cell line and by performing
nuclear fractionation followed by immunoblot analysis of nuclear Keap1 levels with and
without DMP treatment.
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Figure 10

Figure 10. Schematic illustration of a proposed alternative model of the Nrf2-Keap1
pathway of gene regulation (modified from Nguyen et al., 2005). In this model, newly
translated Nrf2 translocates into the nucleus and binds the ARE to maintain basal
expression cytoprotective proteins. Afterwards, Nrf2 dissociates from the ARE and binds
with nuclear Keap1, which facilitates the poly-ubiquitylation and subsequent
nucleocytoplasmic shuttling of Nrf2 to the cytosol for degradation via the 26 S
proteasome. It is possible that DMP activates Nrf2 through this pathway, either by
inhibiting the binding of Nrf2 to Keap1 within the nucleus, or by impairing the ability of
Keap1 to enter the nucleus at all.
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4.4

DMP activates Nrf2 via a non-canonical mechanism

Earlier studies, as well as data presented here, have shown that DMP is protective against
mHTT-induced toxicity in the same PC12 cell line, and 3-NP-induced toxicity in
STHdhQ111 cells (Pitts et al., 2012). However, when the protection against 3-NP-induced
toxicity elicited by DMP was compared to that of a canonical Nrf2 activator,
sulforaphane, it became evident that its protective effects are not due to Nrf2 activation
alone: while DMP enhanced viability in 3-NP-treated STHdhQ111 cells with an optimal
concentration of 10µM, sulforaphane was not protective and actually potentiated 3-NPinduced toxicity at concentrations above 0.5µM (Appendix: Figure I). These observations
suggest that, although both compounds are capable of Nrf2 activation, DMP may utilize a
non-canonical mechanism of Nrf2 activation that is particularly protective against 3-NP
toxicity. Recently, studies have elucidated a non-canonical, p62-dependent induction of
Nrf2. This mechanism involves the direct interaction between p62 and Keap1 such that
Keap1 is sequestered into autophagosomes for degradation, which disrupts the
ubiquitination of Nrf2, allowing for activation of the Nrf2 pathway (Komatsu et al., 2010;
Lau et al., 2010). Interestingly, p62 overexpression significantly decreases the half-life of
Keap1, while p62 knockdown increases it; this implies that p62 plays a crucial role in
regulating Keap1 turnover (Copple et al., 2010). Comparative analysis of STHdhQ7 and
STHdhQ111 whole cell lysates revealed that overall Keap1 protein levels were not reduced
following DMP treatment (Figure 4), which does not support the hypothesis of this study,
in which DMP promotes Nrf2 activity through the p62-mediated autophagosomal
degradation of Keap1. However, taking into account the trend toward increased p62
levels following DMP treatment, it would be prudent to perform additional experiments
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examining overall Keap1 protein levels at a number of time points aside from 24 hours
before claiming that DMP is not promoting autophagosomal degradation of Keap1.

4.5

DMP exposure inhibits the formation of cytoplasmic and nuclear
inclusion bodies containing Keap1

Ubiquitinated protein inclusions are a hallmark of many neurological disorders, including
polyglutamine disorders such as HD, and it has been well established that, in HD, the
mHTT protein misfolds causing the formation of nuclear and cytosolic inclusion bodies.
Interestingly, recent findings revealed that Keap1 co-localizes to neuronal cytoplasmic
inclusions in various neurodegenerative disorders (Tanji et al., 2013). Closer examination
of immunofluorescence data from striatal cells transfected with Nrf2-Flag, which were
co-stained to detect endogenous Keap1, revealed the presence of Keap1-positive
cytoplasmic inclusion bodies, some of which co-localized with Nrf2-Flag, in the
STHdhQ111 but not STHdhQ7 cells (Figure 6). Interestingly, these inclusion bodies were
only detected under basal and 3-NP treatment conditions, suggesting that DMP treatment
decreased the formation of these Keap1 inclusion bodies, both in the presence and
absence of 3-NP. Furthermore, visualization of Keap1-RFP and Nrf2-GFP in STHdhQ111
cells by time-lapse fluorescence microscopy also revealed the formation of cytoplasmic
inclusion bodies containing both exogenous proteins; these inclusion bodies were also
prevented by DMP exposure (Figure 8). In addition, closer examination of immunoblot
analysis of whole cell lysates revealed a high-molecular weight Keap1 band in 3-NP
treated STHdhQ111 cells, which could be reflective of an aggregated form of Keap1
(Figure 4). Separate experiments performed in the Cumming lab also found that coexpression of Keap1-RFP with mHTT-GFP in the PC12-103Q cell model of HD resulted
in co-localization of both proteins in large puncta, which are prevented by DMP exposure
(Appendix: Figure II). Although the role that protein aggregates play in neurotoxicity
remains unclear, there is a strong argument that the elimination of these inclusions may
be effective in attenuating neurodegenerative pathogenesis. Some studies have provided
evidence for an inherent toxicity of aggregation of some proteins not implicated in any
diseases, which suggests that perhaps the abnormal protein conformation is, in its self,
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cytotoxic (Bucciantini et al., 2002). To further assess the inherent cytotoxic properties of
aggregated Keap1, time-lapse fluorescence imaging of ectopically expressed Keap1-RFP
was performed in a more transfection-tolerant hippocampal cell line (HT22 cells). This
experiment revealed a progressive accumulation of Keap1-RFP inclusion bodies that
preceded cell death. In contrast, DMP treatment directed Keap1-RFP to small vesicle-like
structures, which was correlated with prolonged cell survival (Figure 9). These findings
indicate that DMP may work through an autophagosomal mechanism; however, it may be
simply preventing the sequestration of Keap1 and Nrf2 into these puncta. Future studies
should focus on immunoprecipitation assays to look for changes in direct interactions
between Keap1–Nrf2, Keap1–p62, and Keap1–mHtt following DMP treatment.
Additionally, it would be beneficial to observe the interactions and subcellular
localization of these key proteins via time-lapse fluorescence microscopy in a cell line
that is more tolerant of transfection reagents.

4.6

Analysis of the different cell culture models of HD

A number of in vitro models have been developed to study the intracellular mechanisms
associated with HD pathology; cell culture models are also often the starting point in
identifying the beneficial targets of novel pharmacotherapy agents. An increase in mHTT
aggregates has been strongly associated with toxicity in in vitro models of HD (Hackam
et al., 1998), and expression of the truncated mHTT is representative of a delayed disease
progression, whereas expression of the full-length mHTT protein would more accurately
depict the natural disease progression (Dong et al., 2012). The commonly used PC12103Q and PC12-25Q cell lines, which were used in previous studies in this lab, are
immortalized cells derived from a rat pheochromocytoma, which have been transfected
with an ecdysone-inducible protein containing the first 17 amino acids of HTT plus 103
or 25 glutamines fused with enhanced GFP. Although some aspects of the pathological
role of mHTT can be effectively studied in these cells, HD involves the targeted
degeneration of striatal MSNs, which are characteristically distinct from PC12 cells.
Additionally, PC12 cells express only a truncated version of the mHTT protein, and the
protein’s fusion to GFP likely increases its predisposition for aggregation and therefore
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toxicity. The cell lines used in this investigation are immortalized cells derived from the
striatum of transgenic mouse models of HD that have either 7 (STHdhQ7) or 111
(STHdhQ111) CAG repeats within exon 1 of the mHtt gene, and express the full length
wild-type and mutant HTT, respectively (Trettel et al., 2000). Although these cells
express the full-length HTT protein, and are more representative of MSNs, there are a
number of drawbacks associated with their use. Firstly, the transfection efficiency of the
striatal cells was quite poor, and seemed to cause hypersensitivity to xenobiotic and
oxidative stress, especially in the STHdhQ111 cells. This made the use of overexpression
constructs for immunofluorescence and live cell fluorescence experiments difficult and
questionable; very few cells retaining both the Nrf2-GFP and Keap1-RFP constructs
survived treatment, and, by imaging the few that did, we may have been selecting for a
transfection-tolerant cell type. The protein expression levels and oxidative stress
sensitivity also seemed to vary substantially depending on the passage number, which
made the completion of experimental replicates problematic. Furthermore, as indicated
by the Coriell Institute, after passage number 10-12 the mHTT protein is no longer
reliably expressed, so cells were not used after passage number 10. In addition, this
investigation revealed that the STHdhQ111 cells also do not display differential sensitivity
to 3-NP treatment compared to STHdhQ7 when they are both grown in high-serum, highglucose media, and both the STHdhQ7 and STHdhQ111 cells are very sensitive to seeding
density; seeding the cells at too high or too low a density resulted in irreversible changes
in proliferation as well as sensitivity to 3-NP. Finally, these cells are immortalized, which
means that they have cancer cell properties as well as neuronal properties; this could
confound findings related to cell signaling pathways that differ between neurons and
cancer cells. It may be beneficial to perform experiments on primary cell cultures taken
directly from the transgenic mouse model, or on the immortalized cell lines, but at the
non-permissive temperature (39°C) for the temperature-sensitive SV40 large T antigen,
to allow the cells to differentiate and behave more like neurons than cancer cells. This
would ensure a uniform seeding density across experiments, and hopefully minimize the
changes in protein expression levels.
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4.7

Conclusions

This investigation provides further evidence of the neuroprotective properties of DMP in
striatal cell lines, which are the most sensitive cell type to mHTT expression in HD
patients. Additionally, this work shows, for the first time, that DMP is able to prevent the
formation of Keap1- and Nrf2-positive inclusion bodies, which are correlated with cell
death. At this time, the mechanism by which DMP exerts its protective effects remains
unclear, although it seems likely that it involves the autophagosomal pathway or
alterations in Keap1-Nrf2 protein interactions. Further study of direct protein interactions
is warranted before definite claims are made. The findings presented here reveal a novel
relationship between mHTT, Keap1, and Nrf2 and suggest that agents that modify the
Nrf2-Keap1 signaling axis may have clinical relevance for treating HD.
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Appendix

Appendix: Figure I. Canonical activator Sulforaphane did not protect against
mHTT toxicity. The abilities of 2,3-dimercaptopropanol (DMP) and sulforaphane (SFN)
to protect against 3-NP-induced toxicity in the striatal cell lines were assessed by MTT
assay. Following a 24-hour treatment with 10mM 3-NP, DMP enhanced viability in the
STHdhQ111 cells with an optimal concentration of 10µM. Sulforaphane (a classical Nrf2
activator) was not protective and potentiated 3-NP-induced toxicity at concentrations
above 0.5µM. Error bars represent the standard error of the mean cell viability obtained
from four replicates derived one independent experiment.
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Appendix: Figure II. mHTT and Keap1 co-localize in puncta. Fluorescence
microscopy of live PC12 cells co-expressing mHTT fused to GFP (Htt-103Q-GFP) and
Keap1 fused to RFP (Keap1-RFP) revealed co-localization of both proteins in large
perinuclear structures that resemble aggresomes. Treatment with DMP (bottom panels)
led to a sharp decrease in co-localization of Keap1 with mHTT and the appearance of
smaller Keap1 puncta.
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Appendix: Figure III. Neilsen, J. M., & Butt, E. M. (1955). Treatment of Huntington’s
chorea with bal. Bull. Los Angel Neuro Soc. 20, 38-39.
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